All In Biotech

Drug Trial Radar · NCT00756028

Short Versus Long Protocol for IVF and IVF+ICSI

Short Versus Long IVF-treatment. A Prospective, Consecutive and Randomized Comparative Study

Last checked: Nov 20, 2026Latest source record: Jan 13, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,099 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,099

Actual

Start

Jan 2009

Primary completion

Dec 2014

Study completion Dec 2015

Sponsor

Lead sponsor
Peter Hornnes, MD, DMScAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 19, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 39 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Purpose: Comparing a GnRH agonist and an antagonist protocol for IVF/ICSI with regard to 1. frequency of ovarian hyperstimulation syndrome (OHSS) (1. outcome measure) 2. quality of life (2. outcome measure) 3. live birth rate (2. outcome measure) 4. gene expression profiles of granulosa and cumulus cells, and concentrations of estradiol and vascular endothelial growth factor in follicular fluid(not only compared between GnRH agonist and antagonist protocol, but also between patients with OHSS and no OHSS and patients becoming pregnant and not becoming pregnant (2. outcome measure), and 5. number of oocytes removed per treatment, number of embryo transfers per treatment and number of spontaneous abortions per treatment (these three parameters are tertiary outcome measures). In addition to the above mentioned efficacy outcome measures the safety outcome measure "frequency of known side-effects" will be compared between the two protocols.

Conditions

  • Infertility
  • Ovarian Hyperstimulation Syndrome
  • Quality of Life
  • Live Birth

Interventions

  • Patients receiving short protocol IVF/ICSI-treatment.Drug

    Injection s.c. Orgalutran® (Ganirelix)0.25 mg once daily from day 5 of FSH-stimulation until HCG-day

  • Long protocolDrug

    Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®:Nafarelin)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Ovarian Hyperstimulation Syndrome (OHSS)Time frame: 3 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Dronninglund Fertility Clinic

    Dronninglund, Denmark

  • Fertility Clinic, Hvidovre Hospital

    Hvidovre, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.